We understand liver disease, inflammation and fibrosis research, development and commercialization. As a company we are focused on therapies that have the potential to improve the lives of people with non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
In this section you can learn more about cenicriviroc (CVC) and evogliptin (EVO). You can also find information on our research and clinical trial programs.
We are developing CVC for numerous indications. Please see our pipeline graphic below to explore more about our products and indications.
NASH and Supporting Clinical Studies
Phase 2b Primary endpoint Q3 2016
Phase 2a Metabolic Parameters, full data Q4 2016
CVC + EVO
Clinical Studies to start 2016
Other Combination Studies
Primary Scierosing Cholangitis (PSC) Enrolling
Key markers for kidney function to be measured in CENTAUR
Phase 2b (complete); Adjunctive Care Settings (ongoing)